News

Oxidized limonene: New culprit in allergic dermatitis


 

AT THE EADV CONGRESS

ISTANBUL, TURKEY – Oxidized R-limonene, found in more than 60% of personal care and hygiene products, has been found to be a major cause of fragrance allergy, according to the findings of a large, international, patch test study.

Overall, 5.2% of almost 3,000 patients had a positive patch test result for oxidized limonene, and 37% of those reactions were deemed to be clinically relevant. Shampoos, soaps, perfumes, domestic cleaners, sunscreens, and massage creams are among the household products likely to contain limonene, Dr. Johanna Bråred Christensson said at the annual congress of the European Academy of Dermatology and Venereology. R-limonene is also used in high concentrations in industry as a solvent and degreaser.

R-limonene is structurally a fragrance terpene, with a citrus odor. It is found in nature and produced industrially in mass quantities. In its pure form, R-limonene is nonallergenic or at most a weak allergen. However, when R-limonene is oxidized, it includes limonene hydroperoxides, which Dr. Christensson found to be a contact allergen. This oxidation can occur during storage or handling of R-limonene. The hydroperoxides are often already present in containers of R-limonene when shipped from chemical plants to manufacturers of consumer products, according to Dr. Christensson, a dermatologist at the University of Gothenburg (Sweden).

A stable oxidized R-limonene 3.0% in petrolatum with a controlled 0.33% concentration of limonene hydroperoxides, which is commercially available as a patch test material, was used in the patch test study of 2,900 consecutive dermatitis patients who presented to contact dermatitis clinics in Sweden, Denmark, the United Kingdom, Spain, Australia, and Singapore. Participants completed a questionnaire assessing the relevance of a positive patch test result as indicated by exposure to limonene-containing products on the area of their dermatitis.

The study was funded by grants from national allergy research centers. Dr. Christensson reported having no relevant financial conflicts.

bjancin@frontlinemedcom.com

Recommended Reading

Tacrolimus 0.03% Favored for Atopic Blepharoconjunctivitis
MDedge Internal Medicine
Omalizumab shows efficacy for refractory chronic idiopathic urticaria
MDedge Internal Medicine
Cat allergy vaccine effects persist at 2 years
MDedge Internal Medicine
Eczema of the eyelids? Think chemical allergy
MDedge Internal Medicine
Dupilumab cuts moderate, severe asthma exacerbations
MDedge Internal Medicine
Epidermolysis bullosa patients rate itching worse than pain
MDedge Internal Medicine
New urticaria guidelines stress simplicity
MDedge Internal Medicine
Hives from showering? Think aquagenic urticaria
MDedge Internal Medicine
Two new trials bolster omalizumab for urticaria
MDedge Internal Medicine
Novel topical agent reduces chronic itch
MDedge Internal Medicine